HYBIO(SZ:300199)2022-12-06 01:44Group 1: Employee Stock Ownership Plan - The third employee stock ownership plan was terminated due to significant changes in regulatory policies and market conditions, despite attempts to adjust it according to new regulations [2] - The company plans to consider launching a new employee stock ownership plan or other equity incentive methods in the future when conditions are favorable [2] Group 2: Impact of Liraglutide Generic Drug - The global market sales for Liraglutide reached $2.7 billion in 2015 and are expected to grow to $3 billion this year, indicating a positive market outlook [3] - The company is actively pursuing ANDA applications for Liraglutide, which is expected to increase demand and enhance its competitive advantage as a preferred supplier of raw materials [3] Group 3: Future Growth Points - The company anticipates growth in the international market, particularly for Liraglutide and Glatiramer, with ongoing international registration efforts [3] - The company is also targeting both regulated and unregulated markets to expand its market share [3] Group 4: National Medical Insurance Inclusion - The company’s products, Terlipressin and Eptifibatide, are considered popular candidates for inclusion in the national medical insurance directory [4] - The relationship between drug inclusion in insurance and price reduction is not direct and depends on market competition [4] Group 5: Market Outlook for Older Products - The sales of older products like Thymopentin are affected by national policies, but they still maintain a strong market presence due to their widespread clinical applications [4] - The company aims to sustain the market scale of older products while seeking continuous growth in its main business [4]